Valeant Pharma (VRX) Debt In Focus Following Bloomberg Article

Valeant Pharma (NYSE: VRX) has moved into negative territory as traders discuss the company's debt following a Bloomberg article: "Valeant's Debt Addiction."

From the article:

But with its deteriorating credit quality, it's possible that the same company to kick off the industry's takeover spree will need to pull back. The catch-22 is that it needs acquisitions to bring in more cash-generating products in order to reduce debt.

At $31 billion, Valeant's debt load is almost sixfold what it was four years ago. That's also a leverage ratio of 7 times Ebitda, compared with a median of 2.3 for members of the Standard & Poor’s 500 index.

The full article can be found here

Shares of VRX last traded down 0.3% to $100.17.

You May Also Be Interested In

• ByteDance Prefers TikTok Shutdown in US if Legal Options Fail - Reuters
• Is China exporting deflation? BoFA weighs in
• AGBA Group Holding (AGBA) selling off into close, down over 17%